查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585803

脑肿瘤药物市场：按类型、治疗方法、患者年龄层、分销管道、最终用户 - 全球预测 2025-2030

Brain Tumor Therapeutics Market by Type (Glioblastoma, Meningioma, Metastatic Brain Tumors), Therapy (Chemotherapy, Gene Therapy, Immunotherapy), Patient Age Group, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年脑肿瘤药物市值为30.3亿美元，预计到2024年将达到32.8亿美元，复合年增长率为8.24%，到2030年将达到52.8亿美元。

脑肿瘤治疗市场的范围和定义包括一系列治疗方法，包括药物、手术干预和放射线治疗，旨在管理和潜在治癒脑肿瘤。对这些治疗的需求源于脑肿瘤在全球范围内的日益流行，而这些疾病的复杂性强调了这些疾病需要专门的治疗。脑肿瘤药物的最终用途主要是在医院、专门的癌症治疗中心和研究机构，其重点是患者的即时治疗和更有效治疗方法的长期研究。影响市场的主要成长要素包括标靶治疗和免疫疗法等药物开发的技术进步、製药公司增加研发投资以及提高对早期诊断和治疗方案的认识。潜在的机会在于越来越多地采用个人化医疗方法和人工智慧的整合，以提高诊断和治疗的准确性。然而，治疗成本高、监管障碍和临床试验复杂性等挑战对市场成长造成了重大限制。此外，脑肿瘤和血脑障壁的异质性对开发有效的治疗方法提出了独特的科学挑战。为了克服这些问题，寻找新的治疗方法，例如基因疗法、基于奈米粒子的药物传输系统以及使用生物标记进行精准医学，将是创新和研究的最佳领域。这些创新不仅有可能提高治疗效果，还可以减少与传统治疗相关的副作用。在旨在扩大产品系列的持续进步和收购的推动下，市场竞争激烈。为了实现成长，相关人员正在关注研发策略伙伴关係，简化临床试验，并创建可扩展的、具有成本效益的解决方案，以满足各种类型脑肿瘤治疗方法中未满足的需求。

主要市场统计
基准年[2023] 30.3亿美元
预测年份 [2024] 32.8亿美元
预测年份 [2030] 52.8亿美元
复合年增长率（%） 8.24%

市场动态：揭示快速发展的脑肿瘤药物市场的关键市场洞察

供需的动态交互作用正在改变脑肿瘤药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 脑肿瘤和其他神经系统疾病的发生率上升
    • 检测肿瘤是否存在的测试需求日益增长
    • 分子诊断研究活动
  • 市场限制因素
    • 诊断和治疗高成本
  • 市场机会
    • 增加医疗支出和有利的报销政策
    • 政府提高癌症意识的倡议
  • 市场挑战
    • 与脑肿瘤药物相关的副作用

波特五力：驾驭脑瘤药物市场的策略工具

波特的五力框架是了解脑肿瘤药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解脑肿瘤药物市场的外部影响

外部宏观环境因素在塑造脑肿瘤药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解脑肿瘤治疗药物市场的竞争状况

脑肿瘤药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV定位矩阵脑瘤治疗市场供应商的绩效评估

FPNV定位矩阵是评估脑肿瘤治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划脑肿瘤药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对脑肿瘤药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 脑肿瘤和其他神经系统疾病的发生率增加
      • 检测肿瘤是否存在的检验需求增加
      • 分子诊断相关研究活动
    • 抑制因素
      • 诊断和治疗费用高
    • 机会
      • 医疗费用上涨和有利的报销政策
      • 政府提高癌症意识的倡议
    • 任务
      • 与脑肿瘤药物相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章脑肿瘤药物市场：依类型

  • 神经胶母细胞瘤
  • 脑膜瘤
  • 转移性脑瘤
  • 脑下垂体瘤

第七章脑肿瘤药物市场治疗

  • 化疗
  • 基因治疗
  • 免疫疗法
  • 放射治疗
  • 标靶治疗
  • 组织工程

第八章按患者年龄层分類的脑肿瘤治疗药物市场

  • 成人用
  • 小儿科

第九章脑肿瘤药物市场：依通路分类

  • 线下药局
  • 网路药房

第10章脑肿瘤药物市场：依最终用户分类

  • 门诊手术中心
  • 医院
  • 专科诊所

第十一章美洲脑肿瘤药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区脑肿瘤药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲脑肿瘤药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Adcendo ApS
  • AIVITA Biomedical, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aura Biosciences, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • CNS Pharmaceuticals, Inc.
  • Curtana Pharmaceuticals
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies Inc.
  • Gentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Merck KGaA
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi SA
  • Siemens Healthcare GmbH
  • Y-mAbs Therapeutics, Inc.
Product Code: MRR-4342CA326550

The Brain Tumor Therapeutics Market was valued at USD 3.03 billion in 2023, expected to reach USD 3.28 billion in 2024, and is projected to grow at a CAGR of 8.24%, to USD 5.28 billion by 2030.

The scope and definition of the brain tumor therapeutics market encompass a range of treatments including pharmaceuticals, surgical interventions, and radiation therapies aimed at managing and potentially curing brain tumors. The necessity for these treatments arises from the increasing prevalence of brain tumors worldwide, underscored by the complex nature of these conditions, requiring specialized treatments. The application and end-use scope of brain tumor therapeutics are primarily in hospitals, specialized cancer treatment centers, and research institutions, where the focus is on both immediate patient care and long-term research into more effective treatments. Key influencing growth factors in the market include technological advancements in drug development, such as targeted therapies and immunotherapies, increased investment in research and development by pharmaceutical companies, and rising awareness about early diagnosis and treatment options. Potential opportunities lie in the growing adoption of personalized medicine approaches and the integration of artificial intelligence for better diagnostic and treatment accuracy. However, challenges such as high treatment costs, regulatory hurdles, and the complexity of clinical trials impose significant limitations on market growth. Furthermore, the heterogeneity of brain tumors and the blood-brain barrier pose specific scientific challenges to developing efficacious treatments. To overcome these, the best areas of innovation and research include exploring novel treatment methods like gene therapy, nanoparticle-based drug delivery systems, and the use of biomarkers for precision medicine. These innovations could not only enhance treatment efficacy but also reduce side effects associated with traditional therapies. The nature of the market is highly competitive, driven by continuous advancements and acquisitions aimed at expanding product portfolios. To harness growth, stakeholders should focus on strategic partnerships for R&D, seek to streamline clinical trials, and invest in scalable, cost-effective therapies that address the unmet needs in treating various types of brain tumors.

KEY MARKET STATISTICS
Base Year [2023] USD 3.03 billion
Estimated Year [2024] USD 3.28 billion
Forecast Year [2030] USD 5.28 billion
CAGR (%) 8.24%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Tumor Therapeutics Market

The Brain Tumor Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of brain cancer and other neurological disorders
    • Rising need for tests detecting the presence of tumors
    • Research activities in the molecular diagnostics
  • Market Restraints
    • High cost associated with the diagnosis and treatment
  • Market Opportunities
    • Rising healthcare expenditure and the favorable reimbursement policies
    • Government initiatives for cancer awareness
  • Market Challenges
    • Side effects associated with brain tumor therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Brain Tumor Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Tumor Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Tumor Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Tumor Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Tumor Therapeutics Market

A detailed market share analysis in the Brain Tumor Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Tumor Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Tumor Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Tumor Therapeutics Market

A strategic analysis of the Brain Tumor Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Tumor Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adcendo ApS, AIVITA Biomedical, Inc., Amgen Inc., AstraZeneca PLC, Aura Biosciences, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, CNS Pharmaceuticals, Inc., Curtana Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eisai Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc., Gentech, Inc., GlaxoSmithKline PLC, Illumina, Inc., Johnson & Johnson Services, Inc., Merck & Co. Inc., Merck KGaA, Novartis AG, Novocure GmbH, Pfizer Inc., Qiagen N.V., Sanofi S.A., Siemens Healthcare GmbH, and Y-mAbs Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Tumor Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Glioblastoma, Meningioma, Metastatic Brain Tumors, and Pituitary Tumors.
  • Based on Therapy, market is studied across Chemotherapy, Gene Therapy, Immunotherapy, Radiation Therapy, Targeted Therapy, and Tissue Engineering.
  • Based on Patient Age Group, market is studied across Adult and Pediatric.
  • Based on Distribution Channel, market is studied across Offline Pharmacies and Online Pharmacies.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of brain cancer and other neurological disorders
      • 5.1.1.2. Rising need for tests detecting the presence of tumors
      • 5.1.1.3. Research activities in the molecular diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the diagnosis and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising healthcare expenditure and the favorable reimbursement policies
      • 5.1.3.2. Government initiatives for cancer awareness
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with brain tumor therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Brain Tumor Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Glioblastoma
  • 6.3. Meningioma
  • 6.4. Metastatic Brain Tumors
  • 6.5. Pituitary Tumors

7. Brain Tumor Therapeutics Market, by Therapy

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Gene Therapy
  • 7.4. Immunotherapy
  • 7.5. Radiation Therapy
  • 7.6. Targeted Therapy
  • 7.7. Tissue Engineering

8. Brain Tumor Therapeutics Market, by Patient Age Group

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Pediatric

9. Brain Tumor Therapeutics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline Pharmacies
  • 9.3. Online Pharmacies

10. Brain Tumor Therapeutics Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Brain Tumor Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Brain Tumor Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Brain Tumor Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adcendo ApS
  • 3. AIVITA Biomedical, Inc.
  • 4. Amgen Inc.
  • 5. AstraZeneca PLC
  • 6. Aura Biosciences, Inc.
  • 7. Bayer AG
  • 8. Becton, Dickinson and Company
  • 9. Bio-Rad Laboratories, Inc.
  • 10. Bristol-Myers Squibb Company
  • 11. CNS Pharmaceuticals, Inc.
  • 12. Curtana Pharmaceuticals
  • 13. Dr. Reddy's Laboratories Ltd.
  • 14. Eisai Inc.
  • 15. Eli Lilly and Company
  • 16. F. Hoffmann-La Roche AG
  • 17. GE HealthCare Technologies Inc.
  • 18. Gentech, Inc.
  • 19. GlaxoSmithKline PLC
  • 20. Illumina, Inc.
  • 21. Johnson & Johnson Services, Inc.
  • 22. Merck & Co. Inc.
  • 23. Merck KGaA
  • 24. Novartis AG
  • 25. Novocure GmbH
  • 26. Pfizer Inc.
  • 27. Qiagen N.V.
  • 28. Sanofi S.A.
  • 29. Siemens Healthcare GmbH
  • 30. Y-mAbs Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. BRAIN TUMOR THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRAIN TUMOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRAIN TUMOR THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023